Drugs / Human umbilical cord tissue-derived mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02237547 | Sep 2014 → Jan 2019 | spinal cord injury | Translational Biosciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02237846 Comparator | Sep 2014 → Nov 2018 | osteoarthritis, knee | Translational Biosciences | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human umbilical cord tissue-derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237846 ↗ |
| Known as | UC-MSC | “Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected...” NCT02237547 ↗ |
| Modality | Cell therapy | “Human umbilical cord tissue-derived mesenchymal stem cells” NCT02237846 ↗ |
| Route | Intrathecal | “administered intrathecally and intravenously multiple times over the course of one month” NCT02237547 ↗ |
| Route | Intravenous | “administered intrathecally and intravenously multiple times over the course of one month” NCT02237547 ↗ |